Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Malignant Peripheral Nerve Sheath Tumor
NCT02691026Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- Jun 2016
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in malignant peripheral nerve sheath tumor (MPNST), sponsored by Oslo University Hospital. Primary endpoint: Percentage of patients with at least stable disease (CR, PR, or SD) at 18 weeks. Started Jun 2016; status: terminated.
02
Drugs
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT02691026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691026.